Company Overview of Athenex
Athenex, a specialty oncology pharmaceutical company, focuses on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. It offers Oraxol, an oral formulation of paclitaxel that allows for the oral delivery of paclitaxel when combined with Hanmi Pharmaceutical’s absorption enhancer HM30181, a potent and selective P-glycoprotein (PGP) pump inhibitor. The company also provides Oratecan, an oral formulation of Irinotecan for oncology indications, such as colorectal cancers; KX01 (KX2-391), an orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization; and KX02 (KX2-361), a dual Src/pre-tubulin...
701 Ellicott Street
Buffalo, NY 14203
Founded in 2003
Key Executives for Athenex
Chairman and Chief Executive Officer
Co-Founder and Chief Scientific Officer
Chief Operating Officer and Director
Compensation as of Fiscal Year 2015.
Athenex Key Developments
Athenex Announces Address Change
Nov 18 15
Athenex has moved its North American headquarters into the Conventus medical office and research building on the Buffalo Niagara Medical Campus.
Athenex to Build Two Drug-Making Plants in China
Oct 17 15
Athenex has reached an agreement to build two drug manufacturing and distribution plants in China. The government in the Banan District of China's Chongqing province has agreed to pay for the land and construction of the two factories, while Athenex will pay to outfit the plants. The government's capital investment in the project is likely to total $200 million for a 400,000-square-foot finished goods and distribution plant and a 120,000-square-foot plant to make active pharmaceutical ingredients. Athenex will spend $75 million on equipment. Work on the plants should begin early 2016. Athenex expects to employ 500 workers at the two factories, and likely will hire more.
Athenex is considering IPO
Sep 21 15
Athenex is considering an IPO, possibly on the Nasdaq stock exchange.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries